-
Can’t Get You Out of My Head: The Huntington’s Disease Symptom That’s More Than Just Repetition
5 min read
Latest News
-
AMT-130 at Four Years: Hopeful Signs, Complex Controls
12 min read
uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.
-
Huntington’s disease therapeutics conference 2020 – Day 1
12 min read
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
-
Screening the entire genome for new drug targets for HD
6 min read
Scientists screen the ENTIRE genome to find new potential therapeutic targets for HD. This ambitious study provides a wealth of data for HD researchers
-
The third dimension: using minibrains to understand brain development changes in HD
10 min read
Researchers show that highly expanded CAGs in the HD gene can cause early developmental changes using 3D brain models called organoids. What’d they find?
-
Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement
10 min read
Wave Life Sciences announces that its antisense drug WVE-120102 has lowered mutant huntingtin protein in cerebrospinal fluid, but investors seem disappointed. Rather confusing – what do we know for sure?
-
Could molecular handcuffs lower the protein that causes Huntington's disease?
6 min read
Researchers got surprisingly lucky when looking for drug molecules to pull mutant huntingtin protein into a cellular garbage disposal machine
-
Exciting new Huntingtin lowering tool described
8 min read
Exciting new Huntingtin Lowering work from @SangamoTx and @CHDIfoundation using "Zinc Fingers" to shut down expression of the mutant Huntingtin gene. More details on this exciting new technique here.
-
Details emerge of first Huntington’s disease gene therapy clinical trial
8 min read
UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein using a ‘single-shot’ virus delivery system.
-
Fresh Updates from First Huntingtin Lowering Study Publication
12 min read
Hot off the presses – New publication gives more details about the results of Ionis and Roche's safety study with a Huntingtin-lowering ASO
-
An Updated Trial Design for Roche's Huntingtin Lowering Trial
8 min read
Roche announces an update to the GENERATION HD1 trial after reviewing the ASO open label extension study
-
When interrupting is good: genetic hiccups that protect against Huntington's disease
12 min read
Multiple teams find small differences in the 'CAG repeat' bit of the Huntington's disease gene. They don't directly change the huntingtin protein, but do alter the age of symptom onset. What's behind this enigma and what does it mean for patients?
HDBuzz Trial Tracker
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
